Feltner D, Hill C, Lenderking W, Williams VS, Morlock R. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial. J Psychiatr Res. 2009 Oct;43(15):1224-30.
Gallego R, Codony-Servat J, Garcia-Albeniz X, Carcereny E, Longaron R, Oliveras A, Tosca M, Auge JM, Gascon P, Maurel J. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. Endocr Relat Cancer. 2009 Mar;16(1):311-7. doi: 10.1677/ERC-08-0250
Morlock RJ, Williams VS, Cappelleri JC, Harness J, Fehnel SE, Endicott J, Feltner D. Development and evaluation of the Daily Assessment of Symptoms – Anxiety (DAS-A) Scale to evaluate onset of symptom relief in patients with generalized anxiety disorder. J Psychiatr Res. 2008 Oct;42(12):1024-36.
Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007 Dec;143(12):1559-65.
Michels KB, Rothman KJ. Update on unethical use of placebos in randomised trials. Bioethics. 2003 Apr;17(2):188-204.